for inclusion – Page 7 – Communicable Diseases Research

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Covid-19 (회복)로 병원에 입원 한 환자의 콜히친 : 무작위, 통제, 오픈 라벨, 플랫폼 시험

Randomized Controlled Trial

Published on 2021-12-012022-08-13
Journal: The Lancet. Respiratory Medicine [Category] MERS, SARS, 임상,

Evidence of possible SARS-CoV-2 vertical transmission according to World Health Organization criteria in asymptomatic pregnant women

무증상 임산부에서 세계보건기구 기준에 따른 SARS-CoV-2 수직 전파 가능성의 증거

Article

Published on 2021-12-012022-09-11
Journal: Ultrasound in obstetrics & gynecology : the offici [Category] SARS, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus affected amniotic Amniotic fluid applied Asymptomatic Birth carried categories Cesarean section Chain Reaction Child collected contribute coronavirus coronavirus disease COVID-19 criteria detection rate discharge disease eligible Evidence evidence of FIVE for inclusion Gynecology Health Organization highlight inclusion criteria information investigated Mexico City Mild Mild disease Nasopharyngeal swab Neonatal neonatal death Neonate Newborn newborn testing Obstetric obstetrics occurred polymerase chain polymerase chain reaction positive Pregnancy pregnant women rectal rectal swab Rectal swabs retrieved SARS-CoV-2 SARS-CoV-2 detection SARS-CoV-2 test severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Society Son study population Swab Symptoms the timing the WHO Transmission transmission of SARS-CoV-2 Ultrasound vertical transmission was collected was tested WHO WHO criteria women World Health Organization
[DOI] 10.1002/uog.24787 PMC 바로가기 [Article Type] Article

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

성인에서 에어로졸화된 아데노바이러스 5형 벡터 기반 COVID-19 백신(Ad5-nCoV)의 안전성, 내약성 및 면역원성: 공개 및 무작위 1상 임상 시험의 예비 보고서

Clinical Trial

Published on 2021-12-012022-09-12
Journal: The Lancet. Infectious Diseases [Category] Fulltext, SARS, 임상, 진단,

[키워드] 95% CI Adenovirus adverse event age allergy anti-SARS-CoV-2 approved assigned booster booster vaccination Booster vaccine caused China Chinese Chronic illness clinical trial common adverse event computer-generated COVID-19 COVID-19 vaccine deaths development dose Efficacy elicited enrolled evaluate evaluated fatigue Fever FIVE five group for inclusion geometric mean concentration geometric mean titre group headache High dose IgG IgG antibody individual initial intramuscular Intramuscular injection intramuscular vaccination Laboratory low dose Major material neutralising antibody Neutralising antibody responses occurred Open-label outcome participant Participants phase 1 trial pregnant women preliminary report primary immunogenicity randomisation randomised Randomly receptor Receptor binding Registered reported Safety SARS-CoV-2 Science screened sequence Serious Adverse Event seronegative stratified by sex technology Tolerability translation Trial vaccination Vaccine Viral particles were excluded Wuhan, China
[DOI] 10.1016/S1473-3099(21)00396-0 PMC 바로가기 [Article Type] Clinical Trial

Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine

비활성화된 SARS-CoV-2 백신에 대한 인간 IgM 및 IgG 반응

Article

Published on 2021-12-012022-09-11
Journal: Current medical science [Category] MERS, SARS, 진단, 치료기술,

[키워드] accelerated age All participant All participants all subjects anti-IgG antibody Antibody Response Antibody responses COVID-19 COVID-19 pandemic defined dose dose of vaccination Effects effort elicited Factor female for inclusion had no healthy individuals Human IgG antibodies IgG antibody IgM IgM and IgG IgM and IgG antibody responses in healthy individual inactivated inactivated SARS-CoV-2 vaccine. individual less male no effect Older positive result recipients response Retrospective study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine second dose seropositive significantly higher significantly lower subject vaccination vaccine candidates were assessed
[DOI] 10.1007/s11596-021-2461-8 PMC 바로가기 [Article Type] Article

Factors Associated with 90-Day Mortality in Invasively Ventilated Patients with COVID-19 in Marseille, France

Article

Published on 2021-11-302022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] acute respiratory distress syndrome age Analysis ARDS carried Clinical characteristics Cohort Comorbidity conducted COVID-19 determine elevated eligible Factor for inclusion France ICU ICU admission ICUs intensive care unit Invasive mechanical ventilation invasively ventilated patient invasively ventilated patients laboratory-confirmed management Marseille mechanical ventilation mechanically ventilated patients median Mortality multivariable analysis number of comorbidity Occurrence Patient patients with COVID-19 predictor Primary outcome Prognostic factors Respiratory failure Retrospective study risk factor Risk factors SARS-CoV-2 severity statistical analysis thrombosis university hospital Ventilation with COVID-19
[DOI] 10.3390/jcm10235650 PMC 바로가기 [Article Type] Article

The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data

Review

Published on 2021-11-292022-10-28
Journal: Substance Abuse Treatment, Prevention, and Policy [Category] COVID-19, MERS, SARS,

Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial

잠비아 Lusaka의 ART 전달과 시설 기반 HIV 치료의 두 가지 커뮤니티 모델에서 안정적인 HIV를 가진 사람들의 바이러스 억제 비율 : HPTN 071 (POPART) 시험에 중첩 된 클러스터 랜덤 화, 비 회개 시험.

Articles

Published on 2021-11-262022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 95% CI Abuse AIDS allergy Antiretroviral therapy ART assigned Care clinic clinician club Cohort Community Coverage death defined drug Drug Abuse effective Effectiveness eligible Emergency enrolled enrolment Evidence feasibility Final finding Follow-up for inclusion foundation funding group had no HBD health condition HIV Impact individual Infectious diseases initiative less Melinda Gate Melinda Gates mental health National non-inferiority margin non-inferiority trial participant Participants patients plan President Prevalence primary endpoint Primary outcome proportion provided Randomly Rate receiving relief risk risk difference RNA copy screened SOC Standard of care Support suppressed Treatment Trial Viral Viral load virological suppression with HIV written Informed Consent zone
[DOI] 10.1016/S2352-3018(21)00242-3 PMC 바로가기 [Article Type] Articles

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma

Conference abstract

Published on 2021-11-232022-10-05
Journal: Blood [Category] 유전자 메커니즘,

[키워드] addition Affect antibody Antibody Response Antibody titer Antigen AstraZeneca authors average Bayer Bluebird BMS board Cancer CAR Cell cellular immunity Characteristics conducted COVID COVID-19 COVID-19 antibody COVID-19 infection COVID-19 vaccination COVID-19 vaccine CRBN current Daichii Sankyo Debiopharm Deceased died download education eligible evaluated False positive figure for inclusion Frequency funding Genmab Glaxo healthy donors hematologic Hematologic malignancy humoral IgG antibody Immunocompromised Immunoglobulin immunologic response immunosuppressive individual Infection janssen life majority malignancies Mayo Clinic median medical records Mortality multicenter Multiple Multiple myeloma Myeloma national guideline NHL Non-Hodgkin Lymphoma offered Patent Patient Pfizer populations positive receive receptor recipient recipients Regeneron reported response Retrospective study SARS-CoV-2 Seattle Seroconversion seroconversion rate small sample size speaker submission survived T-cell tested the timing the vaccine Therapeutics therapy Treatment Trillium vaccination
[DOI] 10.1182/blood-2021-151859 [Article Type] Conference abstract

Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis

Article

Published on 2021-11-182022-10-30
Journal: Journal of Fungi [Category] COVID-19,

Telepharmacy during COVID-19: A Scoping Review

Review

Published on 2021-11-112022-10-29
Journal: Pharmacy: Journal of Pharmacy Education and Practice [Category] COVID-19,